Author

Hilde T. van der Galiën

Observed names: H.T. van der Galiën, Hilde T Van Der Galien, Hilde T. van der Galien, Hilde Van Der Galien

Institutions: University Medical Center Groningen, University of Groningen, Frisius MC

Observed institutions: University Medical Center Groningen, University of Groningen, Medisch Centrum Leeuwarden, Stichting HemoBase, Beatrix Kinderziekenhuis, Frisius MC

ORCID: 0000-0003-4940-3321

Observed ORCID: 0000-0003-4940-3321

OpenAlex ID: A5074537099

ALL-tRNAseq enables robust tRNA profiling in tissue samples

2023 · Chantal Scheepbouwer, Ernesto Aparicio-Puerta, et al. · Genes & Development · 39

Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia

2018 · Hilde T. van der Galiën, Erik A. H. Loeffen, et al. · Supportive Care in Cancer · 33

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting

2018 · H.T. van der Galiën, M. Hoogendoorn, et al. · Annals of Oncology · 8

Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin’s lymphoma and primary mediastinal B-cell lymphoma

2018 · Rayan H.M. Alkhawtani, Walter Noordzij, et al. · Nuclear Medicine Communications · 8

Patients With Relapsed Large B‐Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months

2025 · Hilde T. van der Galiën, Hilde A. M. Kooistra, et al. · European Journal Of Haematology · 4

Early ICANS recognition with a novel electroencephalogram-based deltawave detection system in patients receiving CAR T-cell therapy

2025 · Marieke Tienstra, Tatum N. Storck, et al. · Blood Immunology & Cellular Therapy · 3

Transformed FL shows improved survival after CAR T-cell therapy compared to de novo LBCL, but early transformation (<12 months) defines a poor-risk subgroup: Results from a nationwide cohort

2025 · Hilde Van Der Galien, Pim Mutsaers, et al. · Blood · 1

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

2025 · Gloria Iacoboni, Victor Navarro, et al. · Blood

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

2025 · Gloria Iacoboni, Emmanuel Bachy, et al. · Blood

Patients with Relapsed Large B-Cell Lymphoma after 12 Months Have a Similarly Poor Prognosis As Patients with a Relapse before 12 Months

2023 · Hilde T Van Der Galien, Hilde AM Kooistra, et al. · Blood

Predictive value of biomarkers and clinical risk criteria for bacterial infection and sepsis in children with cancer and febrile neutropenia.

2014 · Hilde T. van der Galiën

Works count: 11

Citation count: 96

H-index: 4

I10-index: 2